January, 2022

GSK loses R&D chief Barron to high-powered startup amid investor pressure

Bio Pharma Dive

Hal Barron, a key figure in GSK's efforts to revitalize its drug research, will step down as its top scientist at a time when the company is feeling heat from investors to deliver faster growth

Drug company profiteering

World of DTC Marketing

A cancer medication called Xtandi costs $189,800 per year and was developed with taxpayer dollars. The U.S. government has a responsibility for ending the exclusive patents that give them their profits.


Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDUFA VII: More Changes Coming in the Latest Reauthorization


As we noted in a separate blog post , the forthcoming reauthorization of the FDA’s Prescription Drug User Fee Act (PDUFA VII) includes several provisions that are expected to help advance cell and gene therapy products, as well as therapies designed to treat rare diseases.

Feelings of fatigue predict death in older adults


PITTSBURGH, Jan. 24, 2022 – How fatigued certain activities make an older person feel can predict the likelihood death is less than three years away, according to research published today in the Journal of Gerontology: Medical Sciences by University of Pittsburgh epidemiologists.

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

Surprised by a Medical Bill? Here’s What to Do.

Triage Cancer

If you’ve ever been surprised by a medical bill, you’re not alone. An estimated 10 million patients a year receive the shock of unexpectedly high medical bills for emergency or out-of-network care from providers they did not choose.

More Trending

5 questions facing biotech M&A in 2022

Bio Pharma Dive

Analysts expect that deal engines are ready to start firing again following the recent quiet period. Still, uncertainty remains about how biopharma acquisitions could play out in the coming months

Pharma’s outdated hiring practices

World of DTC Marketing

One of the reasons it’s a job-seekers market because candidates today want more from their employers. They want a good work-life balance and want to be valued as a contributor to the success of their company. We live in an instant gratification world.

Which PCD Products Are The Best To Start A Pharma Franchise?

Fossil Remedies

We know that the PCD Pharma Franchise business is lucrative and profitable. But do we know which PCD products should we pick so that the maximum profitability is ensured? Perhaps no. This blog is an attempt to clarify the concepts about choosing the best products. First, choose the right company.

Finally: A comprehensive diagnostic guide to a well-established boxwood disease


For more than 150 years, Volutella blight has been one of the most common diseases of the loved and iconic boxwood plant as well as other plants in the family, including pachysandra and sarcococca. Despite its presence on every continent except Antarctica, the disease can be hard to identify.

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

Abbott CEO Ford showcases new ‘biowearable’ line at CES

Pharma Phorum

US medical device company Abbott has said it plans to launch a new range of ‘biowearable’ health devices aimed at consumers, in a move that builds on its expertise in glucose monitoring.

NervGen Pharma sets sights on trial for spinal-cord injury treatment

Outsourcing Pharma

The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern Universityâs Shirley Ryan AbilityLab. Clinical Development

Pfizer expands into gene editing with Beam research deal

Bio Pharma Dive

Pfizer's work with mRNA vaccines led it explore other applications of the technology, resulting in a multi-year partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases

The financial toxicity of treating cancer

World of DTC Marketing

(Stat News) Today, a study followed 380 patients being treated at community oncology groups across the U.S. after they were diagnosed with metastatic colon cancer. They told the researchers that insurance didn’t protect them from serious money problems.

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

Vir Biotechnology and Bill & Melinda Gates Foundation to develop vaccinal antibody tech for tackling HIV and malaria

BioPharma Reporter

Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a âvaccinal effectâ for the treatment of HIV and prevention of malaria. Bio Developments

With $2 million grant, UTA scientist aims to create massive cancer database


University of Texas at Arlington computer scientist Jacob Luber has earned a five-year, $2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to create a database that contains every publicly available cancer dataset from the National Cancer Institute (NCI).

The 2022 Future Forecast for Pharma Marketing

Pharma Marketing Network

Tune in to the Pharma Marketing Network and industry experts Novartis, UCB, GSK and others, for a fireside talk on hot topics around what has changed in the last year and how to align your pharma marketing strategies accordingly. Three Panels: . Engaging Oncologists in 2022.

Epizyme Announces Proposed Public Offering of Common Stock

BioTech 365

Epizyme Announces Proposed Public Offering of Common Stock Epizyme Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Epizyme, Inc.

10 clinical trials to watch in the first half of 2022

Bio Pharma Dive

Biotech stocks ended 2021 in a slump. But positive results from eagerly anticipated studies in breast cancer, schizophrenia and Alzheimer's disease could help turn the sector's fortunes around

A realistic view of healthcare in 2022

World of DTC Marketing

Yes, there will be changes in healthcare in the coming years but put away the thoughts that telehealth and wearable devices will revolutionize healthcare. More and more patients demand a level of service they want with the increased costs of health insurance premiums.

Applied Virtual Reality in Healthcare: A comprehensive book on medical XR

Pharma Phorum

New study sheds light on origins of life on Earth


New Brunswick, N.J. 14, 2022) – Addressing one of the most profoundly unanswered questions in biology, a Rutgers-led team has discovered the structures of proteins that may be responsible for the origins of life in the primordial soup of ancient Earth. Credit: Rutgers New Brunswick, N.J.

Stand Up to Cancer research initiative targets pancreatic cancer

Outsourcing Pharma

Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually. Clinical Development

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

BioTech 365

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference Charles River Laboratories to Present at J.P. Morgan Healthcare Conference WILMINGTON, Mass.–(BUSINESS –(BUSINESS WIRE)–$CRL #CRL–Charles River Laboratories International, Inc.


Allogene cleared by FDA to resume 'off the shelf' cancer cell therapy trials

Bio Pharma Dive

A "chromosomal abnormality" that led regulators to halt Allogene's trials was judged to be unrelated to its technology, a finding with important implications for the field of donor-derived cell therapies

The disdain of big pharma

World of DTC Marketing

Drug companies raised the prices on hundreds of medications on Jan. 1, with most prices up 5% to 6% on average.

Making sense of differing digital health funding reports

Pharma Phorum

Digital health venture funding had a ridiculous, bonkers, blockbuster year. On this, everyone can agree, although longtime watchers of the industry will remember that we’ve heard that consistently for the last several years.

Genome 111

Machine learning for morphable materials


Flat materials that can morph into three-dimensional shapes have potential applications in architecture, medicine, robotics, space travel, and much more. But programming these shape changes requires complex and time-consuming computations.

New study finds AstraZeneca booster generates higher antibodies against Omicron

Pharma Times

AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria

Trials 106

Epizyme Announces Pricing of Public Offering of Common Stock

BioTech 365

Epizyme Announces Pricing of Public Offering of Common Stock Epizyme Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Epizyme, Inc.

5 questions facing gene therapy in 2022

Bio Pharma Dive

As record levels of money pour into gene therapy research, biotechs are under increased pressure to address issues related to safety, delivery and overlapping pipelines

Can pharma really leverage social media?

World of DTC Marketing

A Mediabistro survey showed that social networks influence more than 40% of people’s health choices. Tik-Tok, Instagram, and other social media channels may soon be overwhelmed with pharma companies’ content, but is it a good idea?